Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Profound Medical ( (TSE:PRN) ) has issued an announcement.
Profound Medical Corp. has priced a financing of up to $40 million, consisting of a $36 million registered direct offering of 5,142,857 common shares at $7.00 each and a planned $4 million private placement in Canada of up to 571,428 common shares at the same price. The registered direct offering, which carries no warrant coverage and is led by healthcare-dedicated investors alongside existing shareholders, is expected to close around December 22, 2025, while the Canadian private placement, subject to stock exchange and other approvals and a four-month-plus-one-day hold period, is expected to close by December 30, 2025. Profound plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, reinforcing its capital position as it works to scale commercialization of its prostate disease treatment platform. Konik Capital Partners, a division of T.R. Winston and Company, is acting as exclusive placement agent for the registered direct component.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its lead technology, TULSA-PRO, integrates real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound, and closed-loop temperature feedback to perform the TULSA Procedure, a minimally invasive treatment with potential application across the full spectrum of prostate disease, from low- to high-risk prostate cancer and patients with both cancer and benign prostatic hyperplasia.
Average Trading Volume: 21,410
Technical Sentiment Signal: Buy
Current Market Cap: C$313.1M
See more insights into PRN stock on TipRanks’ Stock Analysis page.